NovaBridge Biosciences (NBP) Q2 2026 earnings summary

Executive summary

• New CEO Srishti Gupta and CCO Mark Hagler outlined a vision focused on bridging science and patient impact, emphasizing disciplined execution and capital allocation.

• Advanced lead programs givastomig (oncology) and VIS-101 (ophthalmology), achieving key clinical milestones and demonstrating a flexible, strategic approach.

• Enhanced segment disclosure and reporting structure to provide clearer performance visibility.

• The company is exploring growth platforms in Europe and women's health, leveraging business development and clinical expertise.

Financial highlights

• As of June 30, 2026, cash and investments totaled $215.9 million, with $190.6 million in cash/cash equivalents and $25 million in equity investments.

• Research & development expenses rose to $14.3 million for H1 2026, up from $4.1 million year-over-year, driven by clinical development investments.

• Administrative expenses increased to $26.4 million from $8.3 million year-over-year, mainly due to higher share-based compensation, personnel costs, and a one-time write-off of deferred offering costs.

• Net loss was $37.9 million for H1 2026, compared to $8.7 million in H1 2025; net loss per share was $0.14 versus $0.05.

• The company maintains a debt-free balance sheet, providing financial flexibility for upcoming clinical and strategic milestones.

Outlook and guidance

• Givastomig: Updated phase Ib data to be presented at ESMO in October; phase III initiation targeted for late 2026 or as early as year-end 2026, pending planning and financing.

• VIS-101: Phase IIb study initiation planned for the second half of 2026, with global phase III development as a goal for 2027.

• Cash runway projected to support advancement through multiple clinical and strategic milestones, including givastomig's phase III interim data read-out in 2028.

• Ongoing focus on advancing both lead programs and monitoring partnered assets such as ragistomig and uliledlimab.